Global JE (Japanese Encephalitis) Vaccine Market Report and Forecast 2023-2028

According to the report, the global JE (Japanese encephalitis) vaccine market attained a value of USD 238.9 million in 2022. Aided by the increase in the prevalence and incidence of Japanese encephalitis disease, the market is projected to further grow at a CAGR of 6.8% between 2023 and 2028 to reach a value of USD 330.00 million by 2028.

Japanese encephalitis (JE) is a virus spread by mosquitoes that mostly affects the central nervous system and causing inflammation of the brain. The disease is prevalent in several countries across Asia and the Western Pacific regions. JE vaccines are essential in preventing the infection and controlling its spread, as there is no specific treatment for the disease, and it can result in severe neurological complications or even death.

The global JE (Japanese encephalitis) vaccine market growth is primarily driven by the increased awareness of the disease and the importance of vaccination. Governments and international health organisations, such as the World Health Organization (WHO), are undertaking extensive vaccination campaigns to prevent the spread of JE, especially in endemic countries. These efforts have resulted in a higher demand for JE vaccines, propelling the growth of the market.

Advancements in vaccine development and production technologies have also contributed to the growth of the global JE (Japanese encephalitis) vaccine market. Researchers and manufacturers are constantly working to develop more effective and safer vaccines, including live attenuated, inactivated, and recombinant vaccines. These innovations have led to the availability of a broader range of JE vaccines, catering to different age groups and immunisation schedules.

The rising prevalence of global travel and the expansion of JE-endemic regions have further accelerated the global JE (Japanese encephalitis) vaccine market demand. As international travel increases, the risk of the disease spreading to non-endemic countries also rises. Consequently, travellers visiting JE-endemic regions are recommended to get vaccinated, thereby boosting the demand for JE vaccines.

The global JE (Japanese encephalitis) vaccine market expansion is also supported by the growing investments in research and development by both public and private entities. These investments aim to develop novel vaccines, improve existing ones, and expand production capacities to meet the growing demand. Thus, the increased focus on R&D is expected to drive further innovation and expansion in the JE vaccine market during the forecast period.

Market Segmentation

The market can be divided based on type, distribution channel, and region.

Market Breakup by Type

• Inactivated
• Recombinant
• Live Attenuated

Market Breakup by Distribution Channel

• Hospitals
• Retail
• Online

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and acquisitions and mergers, among other major developments, of the global JE (Japanese encephalitis) vaccine companies. Some of the major key players explored in the report are as follows:

• Valneva SE
• Sanofi
• Bharat Biotech International Limited
• Chengdu Institute of Biological Products Co. Ltd
• Others

*The publisher always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.